A true partner in the pursuit of expanded healthspan

Cambrian’s scientists and company-building experts closely partner with research teams, offering scientific and organizational insights and support for a significant edge in a complex, rapidly evolving field.


Cambrian’s sourcing and development engine allows us to identify promising science, deploy capital and teams of drug development experts, and provide stewardship to advance new medicines that will lengthen healthspan. By leveraging established expertise and repeatable functional models, we achieve vast efficiencies in execution speed and resource utilization.

Cambrian’s hypothesis-driven approach and industry-leading portfolio of drug candidates provides for multiple “shots on goal” as we endeavor to discover breakthroughs to disrupt the biology of aging – first to treat disease, and ultimately to prevent it.

“Over the next 10 or 15 years, Cambrian wants to bring the way that we treat the diseases of aging into the 21st century by preventing them from happening, instead of waiting for people to get sick, the same way that we learned how to prevent and reverse the pathologies of infectious diseases like smallpox and polio in the 20th century.”

James Peyer

CEO and Founder of Cambrian Biopharma


We combine scientific rigor with an audacious mission: developing transformative, effective and safe therapies to extend healthspan. A crucial aspect of our vision is making these therapies widely available, wherever possible.

A Word from our Founder

Hear from James Peyer as he introduces the industry of Longevity Biotech and describes how biomedical breakthroughs are being translated into therapeutics to extend healthspan.